MedTrace Logo

Digital Evaluations and Technologies Enabling Clinical Translation for AD

NCT05385913 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-12-06

No results posted yet for this study

Summary

The DETECT-AD study (stands for "Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer's Disease") is a new study designed to improve clinical trials for early Alzheimer's disease. DETECT-AD uses specialized home-based digital devices (electronic scale, electronic pill box, under-the-mattress sleep sensor, motion activity sensors, wrist watch activity tracker, driving sensor, and computer software) to see if the devices will improve clinical trial assessments. This 36- month-long study will simulate a clinical trial to determine how well the home system detects clinically meaningful changes. Participants in DETECT will receive a brain scan to assess their risk for developing Alzheimer's Disease.

After the scan, homes will be outfitted with the devices\*. Participants will be asked to simply go about their daily routines while data is collected in the background by the digital devices.

The scientists will see if there is a change in the digital assessments in four key areas of life activity:

mobility (walking speed), cognition (computer use), sleep (sleep times), and socialization (time spent out of home). Participants will be asked to take a daily multivitamin as a study 'drug' to mimic clinical trial conditions. Using these methods, the DETECT study will produce outcome measures that reflect real-world everyday function. Establishing the superiority of these novel methods compared to conventional methods (for example, exams in a clinic) will provide a potential new pathway for speeding the development of muchneeded new treatments for Alzheimer's

Conditions

  • Alzheimer Disease, Early Onset

Interventions

OTHER

Multivitamin-no intervention

No intervention. All participants will be given a multi-vitamin to take for the duration of the study

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute on Aging (NIA)

    collaborator NIH

  • Oregon Health and Science University

    lead OTHER

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-06-30
Completion
2024-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05385913 on ClinicalTrials.gov